In summary, our study supports eNAMPT/TLR4 signaling as a clinically relevant, highly druggable therapeutic target with an eNAMPT-neutralizing biologic therapy identified as a potential strategy to retard the progression of NAFLD from steatosis to fibrosis. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatotic liver disease.